ACC 2022: Unmet Needs and Emerging Therapies in Lipid Management

Erin D. Michos, MD, MHS

May 04, 2022

Erin D. Michos, MD, discusses the clinical implications of results presented at ACC 2022 in the field of lipid management. Dr Michos sees a great opportunity with the results of the APOLLO trial, which addresses an unmet need for therapeutic options in reducing lipoprotein (a) in her patients.

Dr Michos also reviews the subanalysis of the CANTOS study which evaluated the interleukin-1 (IL-1) beta inhibitor canakinumab in patients with chronic kidney disease (CKD). In looking at what is to come, Dr Michos also notes the ongoing phase 3 ZEUS trial which is evaluating IL-6 inhibitors in patients with CKD at high risk for atherosclerotic cardiovascular disease.

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: ACC 2022: Unmet Needs and Emerging Therapies in Lipid Management - Medscape - May 04, 2022.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.